Finnhub•2026-04-20
Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic SymptomsMNPR — Monopar Therapeutics Inc
NASDAQ · Biotechnology · Biotechnology
$53.20-21.42%Market cap368.41M
- Latest Close
- $53.2
- 30-Day Move
- -21.4%
- Market Cap
- $368M
- Shares Outstanding
- 6,680,000
- P/B Ratio
- 3.17
- ROE
- -10.0%
Analyst consensus: Buy · 20 analysts
NASDAQ:MNPRBiotechnology / BiotechnologyDelayed public snapshot
Monopar Therapeutics Inc
A read-only Alphactor snapshot forMonopar Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$53.2
30-Day Move
-21.4%
Market Cap
$368M
Shares Outstanding
6,680,000
P/B Ratio
3.17
ROE
-10.0%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$53.20
-21.4%last 90 delayed daily bars
Market cap$368M
90D High
$76.13
90D Low
$50.22
Avg Volume
245,996
What stands out
MNPR is down 21.4% over the last 30 trading days shown on this page.
Latest operating income is $-17M, which helps anchor the headline ratios with an actual earnings figure.
Fundamentals snapshot
Latest Close
$53.2
30-Day Move
-21.4%
Market Cap
$368M
Shares Outstanding
6,680,000
P/B Ratio
3.17
ROE
-10.0%
ROA
-9.8%
Debt / Equity
0
Current Ratio
51.35
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-17M
Net Income
$-14M
Gross Margin
--
Net Margin
--
Current Ratio
51.35
Debt / Equity
0.00
Quality snapshot
Altman Z
76.37
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.89x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-11M | $-11M | $-7M |
| 2023-12-31 | $0 | $-9M | $-8M | $-8M |
| 2024-12-31 | $0 | $-16M | $-16M | $-6M |
| 2025-12-31 | $0 | $-17M | $-14M | $-12M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-20
Reported Sunday, Monopar Presents Phase 3 Data At AAN 2026 Showing ALXN1840 Delivers Greater Neurologic Benefit And Lower Worsening Rates Versus Standard Of Care In Wilson DiseaseFinnhub•2026-04-19
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 167,986 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 112,803 | 0.02% | 2026-02-28 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 44,400 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 43,450 | 0.01% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | 37,776 | 0.01% | 2026-02-28 |
| BNY Mellon Investment Funds I-BNY Mellon Small/Mid Cap Growth Fund | 28,048 | 0.00% | 2025-12-31 |
| iShares Trust-iShares Core S&P Total U.S. Stock Market ETF | 23,226 | 0.00% | 2026-02-28 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 20,818 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Vanguard Group
Filed 2026-01-29
$19M
+41.1%
Geode Capital Management
Filed 2025-11-12
$7M
-12.3%
Bank of New York Mellon
Filed 2026-02-10
$4M
+277.7%
Northern Trust
Filed 2025-11-14
$2M
-15.6%
Charles Schwab
Filed 2025-11-10
$963,461
-11.0%
Analyst consensus?
Rating(?)
4.2
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
20
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.